# ovarian clear cell carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ovarian-clear-cell-carcinoma

> No upcoming FDA catalysts in ovarian clear cell carcinoma; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for ovarian clear cell carcinoma?

No upcoming FDA catalysts in ovarian clear cell carcinoma; 2 past events are recorded. SEC Form 10-Q: "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." [Calendar and source filings](https://sec-api.dev/indications/ovarian-clear-cell-carcinoma)

Source: SEC Form 10-Q, accession 0001493152-26-023150, https://www.sec.gov/Archives/edgar/data/1335105/000149315226023150/form10-q.htm (retrieved 2026-11-12). Last confirmed 2026-05-14. Cite: https://sec-api.dev/indications/ovarian-clear-cell-carcinoma#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 20, 2023 | [LB-100 trial start](https://sec-api.dev/pdufa/lb-100) | NMAD | ovarian clear cell carcinoma | completed | "September 20, 2023, we announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1335105/000149315226027286/form424b5.htm)) |
| May 15, 2024 | [Andersen trial start](https://sec-api.dev/pdufa/andersen) | NMAD | ovarian clear cell carcinoma | completed | "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1335105/000149315226023150/form10-q.htm)) |

## Drugs

- [LB-100](https://sec-api.dev/pdufa/lb-100) (NMAD)
- [Andersen](https://sec-api.dev/pdufa/andersen) (NMAD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ovarian-clear-cell-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ovarian clear cell carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ovarian-clear-cell-carcinoma

```bibtex
@misc{secapidev_indications_ovarian_clear_cell_carcinoma_20261116,
  title        = {ovarian clear cell carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ovarian-clear-cell-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ovarian_clear_cell_carcinoma_20261116","title":"ovarian clear cell carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ovarian-clear-cell-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
